{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:34:34Z","timestamp":1771004074314,"version":"3.50.1"},"reference-count":26,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,3,10]]},"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the incremental value of new drugs across disease areas receiving favourable coverage decisions by the UK\u2019s National Institute for Health and Care Excellence (NICE) over the past decade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, and participants<\/jats:title>\n                    <jats:p>This cross-sectional study assessed favourable appraisal decisions of drugs between 1 January 2010 and 31 December 2020. Estimates of incremental benefit were extracted from NICE\u2019s evidence review groups reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary outcome measure<\/jats:title>\n                    <jats:p>Incremental benefit of novel drugs relative to the best alternative therapeutic option, expressed in quality-adjusted life-years (QALYs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>184 appraisals of 129 drugs provided QALYs. The median incremental value was 0.27 QALY (IQR: 0.07\u20130.73). Benefits varied across drug-indication pairs (range: \u22120.49 to 5.22 QALY). The highest median benefits were found in haematology (0.70, IQR: 0.55\u20131.22) and oncology (0.46, IQR: 0.20\u20130.88), the lowest in ophthalmology (0.09, IQR: 0.04\u20130.22) and endocrinology (0.02, IQR: 0.01\u20130.06). Eight appraisals (4.3%) found contributions of more than two QALYs, but one in four (50\/184) drug-indication pairs provided less than the equivalent of 1 month in perfect health compared to existing treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In our review period, the median incremental value of novel drugs approved for use within the English National Health System, relative to the best alternative therapeutic option, was equivalent to 3\u20134 months of life in perfect health, but data were heterogeneous. Objective evaluations of therapeutic value helps patients and physicians to develop reasonable expectations of drugs and delivers insights into disease areas where medicinal therapeutic progress has had the most and least impact.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-058279","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T12:15:55Z","timestamp":1649420155000},"page":"e058279","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2720-3479","authenticated-orcid":false,"given":"Tobias B","family":"Polak","sequence":"first","affiliation":[{"name":"Erasmus School of Health Policy & Management, Erasmus University Rotterdam, , Rotterdam, The Netherlands"},{"name":"Department of Biostatistics, Erasmus MC, Rotterdam, The Netherlands"},{"name":"RWD Department, myTomorrows, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6706-5464","authenticated-orcid":false,"given":"David GJ","family":"Cucchi","sequence":"additional","affiliation":[{"name":"Department of Haematology, Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands"},{"name":"Department of Internal Medicine, Franciscus Gasthuis en Vlietland, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan J","family":"Darrow","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4804-235X","authenticated-orcid":false,"given":"Matthijs M","family":"Versteegh","sequence":"additional","affiliation":[{"name":"Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"key":"2025121401340370000_12.4.e058279.1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.600"},{"key":"2025121401340370000_12.4.e058279.2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-6296(88)90030-6"},{"key":"2025121401340370000_12.4.e058279.3","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1111\/j.1524-4733.2009.00515.x","article-title":"QALYs: the basics","volume":"12 Suppl 1","author":"Weinstein","year":"2009","journal-title":"Value Health"},{"key":"2025121401340370000_12.4.e058279.4","doi-asserted-by":"crossref","DOI":"10.2307\/1191310","article-title":"Where now for saving lives?","volume":"40","author":"Zeckhauser","year":"1976","journal-title":"Law Contemp Probl"},{"key":"2025121401340370000_12.4.e058279.5","unstructured":"The National Institute for Health and Care . Guide to the methods of technology appraisal. Nice, 2018: 1\u201393."},{"key":"2025121401340370000_12.4.e058279.6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-052186","article-title":"Real-World data from expanded access programmes in health technology assessments: a review of NICE technology appraisals","volume":"12","author":"Polak","year":"2022","journal-title":"BMJ Open"},{"key":"2025121401340370000_12.4.e058279.7","unstructured":"National Institute for Health and Care Excellence . Single technology appraisal: user guide for company evidence submission, 2018: 1\u201336. https:\/\/www.nice.org.uk\/process\/pmg24\/chapter\/instructions-for-companies"},{"key":"2025121401340370000_12.4.e058279.8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s40273-017-0599-9","article-title":"Venetoclax for treating chronic lymphocytic leukaemia: an evidence review group perspective of a NICE single technology appraisal","volume":"36","author":"Mistry","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"2025121401340370000_12.4.e058279.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810773"},{"key":"2025121401340370000_12.4.e058279.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62125-5"},{"key":"2025121401340370000_12.4.e058279.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1006885"},{"key":"2025121401340370000_12.4.e058279.12","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2016.6008","article-title":"Failure of investigational drugs in late-stage clinical development and publication of trial results","volume":"176","author":"Hwang","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2025121401340370000_12.4.e058279.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.20288"},{"key":"2025121401340370000_12.4.e058279.14","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The strength of association between surrogate end points and survival in oncology","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2025121401340370000_12.4.e058279.15","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1470-2045(20)30730-0","article-title":"Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis","volume":"22","author":"Gharzai","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025121401340370000_12.4.e058279.16","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.8441"},{"key":"2025121401340370000_12.4.e058279.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00486-6"},{"key":"2025121401340370000_12.4.e058279.18","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.0000437068.30550.cf"},{"key":"2025121401340370000_12.4.e058279.19","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-publhealth-031210-101211"},{"key":"2025121401340370000_12.4.e058279.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01164-x"},{"key":"2025121401340370000_12.4.e058279.21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/bjh.17892","article-title":"The wider perspective: twenty years of clinical trials in myelodysplastic syndromes","volume":"196","author":"Duetz","year":"2022","journal-title":"Br J Haematol"},{"key":"2025121401340370000_12.4.e058279.22","doi-asserted-by":"crossref","unstructured":"Cucchi DGJ , Polak TB , Ossenkoppele GJ . The predictive value of a positive phase II ash Abstract for peer-reviewed publication and progression to phase III. Blood.doi:10.1182\/blood.2021013988","DOI":"10.1182\/blood.2021013988"},{"key":"2025121401340370000_12.4.e058279.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30925-9"},{"key":"2025121401340370000_12.4.e058279.24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamaoncol.2015.3931","article-title":"The use of Superlatives in cancer research","volume":"2","author":"Abola","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025121401340370000_12.4.e058279.25","first-page":"38","article-title":"Advies uitbrengen over subgroepen: NVMO-leden steunen aanpassing van werkwijze commissie BOM","volume":"20","author":"Dooper","year":"2017","journal-title":"Med Oncol"},{"key":"2025121401340370000_12.4.e058279.26","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2147\/DDDT.S216056","article-title":"Update on Eluxadoline for the treatment of irritable bowel syndrome with diarrhea: patient selection and perspectives","volume":"14","author":"Liu","year":"2020","journal-title":"Drug Des Devel Ther"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-058279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T09:34:17Z","timestamp":1765704857000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-058279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4,8]]},"published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1136\/bmjopen-2021-058279"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-058279","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}